Pages that link to "Item:Q1929691"
From MaRDI portal
The following pages link to Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials (Q1929691):
Displaying 9 items.
- Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control (Q454783) (← links)
- Incoherent dose-escalation in phase I trials using the escalation with overdose control approach (Q725696) (← links)
- Unifying CRM and EWOC designs for phase I cancer clinical trials (Q1007501) (← links)
- A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate (Q1733138) (← links)
- Number of patients per cohort and sample size considerations using dose escalation with overdose control (Q1929695) (← links)
- Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
- Designs foe phase i cancer clinical trials with differentiation of graded toxicity (Q4548226) (← links)
- A continual reassessment method without undue risk of toxicity (Q6171847) (← links)
- On the properties of the toxicity index and its statistical efficiency (Q6627682) (← links)
